References

Cancer information / Cancer types / Soft tissue sarcoma / Research

Agulnik M, Milhem MM, Rademaker A, et al. A phase II study of tivozanib in patients with metastatic and non-resectable soft tissue sarcomas. (2015). ASCO 2015 Annual Meeting. American Society of Clinical Oncology. Abstract 10515.

Bates JE, Mazloom A, Dhakal S, Constine LS. The benefit of adjuvant radiotherapy in high-grade retroperitoneal sarcoma: A SEER analysis. (2015). ASCO 2015 Annual Meeting. American Society of Clinical Oncology. Abstract 10559.

Chawla SP, Schoffski P, Grignani G, et al. Subtype-specific activity in liposarcoma (LPS) patients (pts) from a phase 3, open-label, randomized study of eribulin (ERI) versus dacarbazine (DTIC) in pts with advanced LPS and leiomyosarcoma (LMS). (2016). ASCO 2016 Annual Meeting. American Society of Clinical Oncology. Abstract 11037.

Demetri GD, von Mehren M, Jones RL, et al. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. (2016). Journal of Clinical Oncology. 34(8):786-793.

Dickson MA, Mahoney MR, Tap WD, et al. Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma. (2016). Annals of Oncology. 27(10):1855-1860.

Harter P, Sehouli J, Reuss A, et al. Phase II study evaluating pegliposomal doxorubicin and carboplatin combination chemotherapy in gynecologic sarcomas and mixed epithelial-mesenchymal tumors a phase II protocol of the Arbeitsgemeinschaft Gynaekologische Onkologie Study Group (AGO-GYN 7). (2016). International Journal of Gynecological Cancer. [Epub ahead of print].

Joensuu H, Eriksson M, Sundby Hall K, et al. Adjuvant imatinib for high-risk GI stromal tumor: analysis of a randomized trial. (2016). Journal of Clinical Oncology. 34(3):244-250.

Kim YJ, Song SY, Choi W, et al. Postoperative radiotherapy after limb-sparing surgery for soft-tissue sarcomas of the distal extremities. (2016). Anticancer Research. 36(9):4825-4831.

Lou Z, Zhang X, Peng W, et al. A phase II study of gemcitabine, vincristine and cisplatin as second-line treatment for patients with advanced soft tissue sarcoma. (2016). Medicine. 94(43):e1777. doi: 10.1097/MD.0000000000001777.

National Cancer Institute. National Cancer Institute Clinical Trials Search. Bethesda: National Cancer Institute.

Penel N, Mir O, Italiano A, et al. Regorafenib (RE) in liposarcomas (LIPO), leiomyosarcomas (LMS), synovial sarcomas (SYN), and other types of soft-tissue sarcomas (OTS): Results of an international, double-blind, randomized, placebo (PL) controlled phase II trial. (2016). ASCO 2016 Annual Meeting. American Society of Clinical Oncology. Abstract 11003.

Schmoll HJ, Russel J, Reichardt P, et al. Pazopanib vs pazopanib + gemcitabine in refractory soft tissue sarcoma: A randomized phase II trial of the AIO. (2016). ASCO 2016 Annual Meeting. American Society of Clinical Oncology. Abstract 11004.

Schoffski P, Chawla S, Maki RG, et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. (2016). Lancet. Elsevier. 387(10028):1629-1637.

Tap WD, Jones RL, Van Tine BA, et al. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. (2016). Lancet. Elsevier. 388(10043):488-497.

Van Tine BA, Agulnik M, Olson RD et al. A phase 2 trial of 5-imino-13-deoxydoxorubicin (GPX-150) in metastatic and non-resectable soft tissue sarcomas. (2016). ASCO 2016 Annual Meeting. American Society of Clinical Oncology. Abstract 11019.

Yihebali C, Yongkun S, Cai J, et al. Phase II study of anlotinib for treatment of advanced soft tissues sarcomas. (2016). ASCO 2016 Annual Meeting. American Society of Clinical Oncology. Abstract 11005.

×
×